泰恩康：关于全资子公司收到巴瑞替尼片药品注册证书的公告

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration [2] Group 1 - The drug registration certificate signifies regulatory approval for Baricitinib tablets, which may enhance the company's product portfolio and market presence [2] - This approval could potentially lead to increased revenue streams for the company through the commercialization of Baricitinib [2]